• Pliant Therapeutics Inc PLRX.OQ reported a quarterly adjusted loss of 95 cents​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -70 cents. The mean expectation of twelve analysts for the quarter was for a loss of 97 cents per share. Wall Street expected results to range from $-1.15 to -87 cents per share.

• Reported revenue was zero​; analysts expected $531.25 thousand.

• Pliant Therapeutics Inc's reported EPS for the quarter was a loss of 95 cents​.

• The company reported a quarterly loss of $57.76 million.

• Pliant Therapeutics Inc shares had risen by 35.5% this quarter and lost 16.1% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 1.3% in the last three months.​

• In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Pliant Therapeutics Inc is $40.00

This summary was machine generated from LSEG data November 8 at 09:08 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)